AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IVVD
  4. [Form 4] Invivyd, Inc. Insider Trading Activity

[Form 4] Invivyd, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Robert D. Allen III, Chief Scientific Officer of Invivyd, Inc. (IVVD), reported RSU vesting and related sell-to-cover transactions. On 08/15/2025 he recorded the vesting of 99,000 restricted stock units, each converting to one share. To satisfy tax withholding, the reporting person sold 18,512 shares on 08/18/2025 at a weighted average price of $0.6502 and 27,420 shares on 08/19/2025 at a weighted average price of $0.5666. Following those transactions, he beneficially owns 53,068 shares directly and reports 201,000 shares beneficially owned in total after accounting for derivative holdings. The sales were made under a Rule 10b5-1 plan adopted on 02/20/2025 and were non-discretionary sell-to-cover transactions for tax purposes. The RSU award vests over 18 months with one-third vesting every six months beginning 02/15/2025.

Robert D. Allen III, Chief Scientific Officer di Invivyd, Inc. (IVVD), ha riportato il vesting di RSU e le relative operazioni di vendita per copertura fiscale. Il 15/08/2025 sono vestite 99.000 unit脿 azionarie vincolate (RSU), ciascuna convertibile in una azione. Per coprire le ritenute fiscali, la persona segnalante ha venduto 18.512 azioni il 18/08/2025 al prezzo medio ponderato di $0,6502 e 27.420 azioni il 19/08/2025 al prezzo medio ponderato di $0,5666. Dopo tali operazioni detiene 53.068 azioni in propriet脿 diretta e dichiara un totale di 201.000 azioni possedute in modo beneficiario, includendo le posizioni in derivati. Le vendite sono state eseguite ai sensi di un piano Rule 10b5-1 adottato il 20/02/2025 e sono state operazioni non discrezionali di tipo sell-to-cover per finalit脿 fiscali. Il premio in RSU matura in 18 mesi, con un terzo che matura ogni sei mesi a partire dal 15/02/2025.

Robert D. Allen III, Director Cient铆fico de Invivyd, Inc. (IVVD), inform贸 el vencimiento de RSU y las ventas relacionadas para cubrir impuestos. El 15/08/2025 se registr贸 el vencimiento de 99.000 unidades restringidas (RSU), cada una convertible en una acci贸n. Para cubrir las retenciones fiscales, la persona informante vendi贸 18.512 acciones el 18/08/2025 a un precio medio ponderado de $0,6502 y 27.420 acciones el 19/08/2025 a un precio medio ponderado de $0,5666. Tras esas transacciones posee directamente 53.068 acciones y declara un total de 201.000 acciones en propiedad beneficiaria, incluyendo participaciones en derivados. Las ventas se realizaron bajo un plan Rule 10b5-1 adoptado el 20/02/2025 y fueron transacciones no discrecionales de tipo sell-to-cover con fines fiscales. El otorgamiento de RSU vence en 18 meses, con un tercio que vence cada seis meses desde el 15/02/2025.

Invivyd, Inc.(IVVD) 靾橃劃 瓿柬暀 毂呾瀯鞛� Robert D. Allen III臧� RSU鞚� 氩犾姢韺� 氚� 鞚挫棎 霐半ジ 靹戈笀 氤挫爠(sell-to-cover) 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 2025-08-15鞐� 99,000臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� 氩犾姢韺呺悩鞐堨溂氅� 臧� 雼渼電� 1欤茧 鞝勴櫂霅╇媹雼�. 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暣 氤搓碃鞚胳潃 2025-08-18鞐� 18,512欤�毳� 臧�欷戫弶攴犼皜 $0.6502鞐�, 2025-08-19鞐� 27,420欤�毳� 臧�欷戫弶攴犼皜 $0.5666鞐� 毵り皝頄堨姷雼堧嫟. 頃措嫻 瓯半灅 頉� 歆侅爲 氤挫湢 欤检嫕鞚� 53,068欤�鞚措┌, 韺岇儩靸來拡 氤挫湢攵勳潉 韽暔頃� 齑� 鞁れ唽鞙� 欤检嫕鞚� 201,000欤�搿� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 鞚� 毵り皝鞚� 2025-02-20鞐� 毂勴儩霅� Rule 10b5-1 瓿勴殟鞐� 霐半澕 鞚措（鞏挫 牍勳灛霟夓爜(sell-to-cover) 瓯半灅鞛呺媹雼�. RSU 靾橃棳攵勳潃 18臧滌洈 霃欖晥 氩犾姢韺呺悩氅� 2025-02-15攵�韯� 毵� 6臧滌洈毵堧嫟 1/3鞌� 氩犾姢韺呺惄雼堧嫟.

Robert D. Allen III, directeur scientifique d'Invivyd, Inc. (IVVD), a d茅clar茅 le vesting de RSU et les op茅rations de vente connexes destin茅es 脿 couvrir les imp么ts. Le 15/08/2025, 99 000 unit茅s d'actions restreintes (RSU) sont devenues acquises, chacune convertible en une action. Pour satisfaire les pr茅l猫vements fiscaux, la personne d茅clarante a vendu 18 512 actions le 18/08/2025 au prix moyen pond茅r茅 de 0,6502 $ et 27 420 actions le 19/08/2025 au prix moyen pond茅r茅 de 0,5666 $. Apr猫s ces transactions, il d茅tient directement 53 068 actions et d茅clare 201 000 actions d茅tenues au total 脿 titre b茅n茅ficiaire, en incluant les positions d茅riv茅es. Les ventes ont 茅t茅 effectu茅es dans le cadre d'un plan Rule 10b5-1 adopt茅 le 20/02/2025 et constituaient des op茅rations non discr茅tionnaires de type sell-to-cover 脿 des fins fiscales. La r茅compense en RSU vest sur 18 mois, avec un tiers qui devient acquis tous les six mois 脿 partir du 15/02/2025.

Robert D. Allen III, Chief Scientific Officer von Invivyd, Inc. (IVVD), meldete das Vesting von RSU und die dazugeh枚rigen Sell-to-Cover-Transaktionen. Am 15.08.2025 wurden 99.000 Restricted Stock Units (RSU) vestingbedingt freigegeben, jede davon wandelbar in eine Aktie. Zur Begleichung der Steuerabz眉ge verkaufte die meldende Person 18.512 Aktien am 18.08.2025 zum gewichteten Durchschnittspreis von $0,6502 und 27.420 Aktien am 19.08.2025 zum gewichteten Durchschnittspreis von $0,5666. Nach diesen Transaktionen besitzt er direkt 53.068 Aktien und gibt insgesamt 201.000 Aktien als wirtschaftlich gehalten an, einschlie脽lich Derivatepositionen. Die Verk盲ufe erfolgten unter einem am 20.02.2025 eingef眉hrten Rule-10b5-1-Plan und waren nicht-diskretion盲re Sell-to-Cover-Transaktionen zur Steuerzahlung. Die RSU-Zuteilung vestet 眉ber 18 Monate, wobei ab dem 15.02.2025 alle sechs Monate ein Drittel vestet.

Positive
  • Use of a Rule 10b5-1 plan adopted 02/20/2025, which reduces concerns about opportunistic insider trading timing
  • Clear disclosure of weighted-average sale prices and offer to provide per-trade details, supporting transparency
  • RSU vesting schedule disclosed (18 months, one-third every six months), clarifying future equity issuance timing
Negative
  • None.

Insights

TL;DR: Routine RSU vesting with sell-to-cover disposals under a 10b5-1 plan; limited market impact.

The transactions reflect scheduled equity compensation vesting and immediate sell-to-cover sales to meet tax obligations rather than open-market liquidations for cash needs. Total direct beneficial ownership decreased from vesting conversions and withholding sales to 53,068 shares, while total reported beneficial ownership including derivative RSUs is 201,000 shares. Prices realized were modest ($0.5524鈥�$0.7134 range cited), and the use of a 10b5-1 plan reduces concerns about opportunistic timing. For investors, this is a routine dilution/settlement event tied to compensation.

TL;DR: Disclosure is standard and transparent; 10b5-1 plan and sell-to-cover mechanics are clearly reported.

The Form 4 details the vesting schedule, the tax-driven sell-to-cover sales, and provides weighted average price ranges with an offer to furnish per-trade breakdowns on request, which supports transparency. The RSU award vesting over 18 months and public reporting of the 10b5-1 adoption date (02/20/2025) align with good governance practices for insider transactions. No indication of discretionary insider trading is present in the filing.

Robert D. Allen III, Chief Scientific Officer di Invivyd, Inc. (IVVD), ha riportato il vesting di RSU e le relative operazioni di vendita per copertura fiscale. Il 15/08/2025 sono vestite 99.000 unit脿 azionarie vincolate (RSU), ciascuna convertibile in una azione. Per coprire le ritenute fiscali, la persona segnalante ha venduto 18.512 azioni il 18/08/2025 al prezzo medio ponderato di $0,6502 e 27.420 azioni il 19/08/2025 al prezzo medio ponderato di $0,5666. Dopo tali operazioni detiene 53.068 azioni in propriet脿 diretta e dichiara un totale di 201.000 azioni possedute in modo beneficiario, includendo le posizioni in derivati. Le vendite sono state eseguite ai sensi di un piano Rule 10b5-1 adottato il 20/02/2025 e sono state operazioni non discrezionali di tipo sell-to-cover per finalit脿 fiscali. Il premio in RSU matura in 18 mesi, con un terzo che matura ogni sei mesi a partire dal 15/02/2025.

Robert D. Allen III, Director Cient铆fico de Invivyd, Inc. (IVVD), inform贸 el vencimiento de RSU y las ventas relacionadas para cubrir impuestos. El 15/08/2025 se registr贸 el vencimiento de 99.000 unidades restringidas (RSU), cada una convertible en una acci贸n. Para cubrir las retenciones fiscales, la persona informante vendi贸 18.512 acciones el 18/08/2025 a un precio medio ponderado de $0,6502 y 27.420 acciones el 19/08/2025 a un precio medio ponderado de $0,5666. Tras esas transacciones posee directamente 53.068 acciones y declara un total de 201.000 acciones en propiedad beneficiaria, incluyendo participaciones en derivados. Las ventas se realizaron bajo un plan Rule 10b5-1 adoptado el 20/02/2025 y fueron transacciones no discrecionales de tipo sell-to-cover con fines fiscales. El otorgamiento de RSU vence en 18 meses, con un tercio que vence cada seis meses desde el 15/02/2025.

Invivyd, Inc.(IVVD) 靾橃劃 瓿柬暀 毂呾瀯鞛� Robert D. Allen III臧� RSU鞚� 氩犾姢韺� 氚� 鞚挫棎 霐半ジ 靹戈笀 氤挫爠(sell-to-cover) 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 2025-08-15鞐� 99,000臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)臧� 氩犾姢韺呺悩鞐堨溂氅� 臧� 雼渼電� 1欤茧 鞝勴櫂霅╇媹雼�. 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暣 氤搓碃鞚胳潃 2025-08-18鞐� 18,512欤�毳� 臧�欷戫弶攴犼皜 $0.6502鞐�, 2025-08-19鞐� 27,420欤�毳� 臧�欷戫弶攴犼皜 $0.5666鞐� 毵り皝頄堨姷雼堧嫟. 頃措嫻 瓯半灅 頉� 歆侅爲 氤挫湢 欤检嫕鞚� 53,068欤�鞚措┌, 韺岇儩靸來拡 氤挫湢攵勳潉 韽暔頃� 齑� 鞁れ唽鞙� 欤检嫕鞚� 201,000欤�搿� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 鞚� 毵り皝鞚� 2025-02-20鞐� 毂勴儩霅� Rule 10b5-1 瓿勴殟鞐� 霐半澕 鞚措（鞏挫 牍勳灛霟夓爜(sell-to-cover) 瓯半灅鞛呺媹雼�. RSU 靾橃棳攵勳潃 18臧滌洈 霃欖晥 氩犾姢韺呺悩氅� 2025-02-15攵�韯� 毵� 6臧滌洈毵堧嫟 1/3鞌� 氩犾姢韺呺惄雼堧嫟.

Robert D. Allen III, directeur scientifique d'Invivyd, Inc. (IVVD), a d茅clar茅 le vesting de RSU et les op茅rations de vente connexes destin茅es 脿 couvrir les imp么ts. Le 15/08/2025, 99 000 unit茅s d'actions restreintes (RSU) sont devenues acquises, chacune convertible en une action. Pour satisfaire les pr茅l猫vements fiscaux, la personne d茅clarante a vendu 18 512 actions le 18/08/2025 au prix moyen pond茅r茅 de 0,6502 $ et 27 420 actions le 19/08/2025 au prix moyen pond茅r茅 de 0,5666 $. Apr猫s ces transactions, il d茅tient directement 53 068 actions et d茅clare 201 000 actions d茅tenues au total 脿 titre b茅n茅ficiaire, en incluant les positions d茅riv茅es. Les ventes ont 茅t茅 effectu茅es dans le cadre d'un plan Rule 10b5-1 adopt茅 le 20/02/2025 et constituaient des op茅rations non discr茅tionnaires de type sell-to-cover 脿 des fins fiscales. La r茅compense en RSU vest sur 18 mois, avec un tiers qui devient acquis tous les six mois 脿 partir du 15/02/2025.

Robert D. Allen III, Chief Scientific Officer von Invivyd, Inc. (IVVD), meldete das Vesting von RSU und die dazugeh枚rigen Sell-to-Cover-Transaktionen. Am 15.08.2025 wurden 99.000 Restricted Stock Units (RSU) vestingbedingt freigegeben, jede davon wandelbar in eine Aktie. Zur Begleichung der Steuerabz眉ge verkaufte die meldende Person 18.512 Aktien am 18.08.2025 zum gewichteten Durchschnittspreis von $0,6502 und 27.420 Aktien am 19.08.2025 zum gewichteten Durchschnittspreis von $0,5666. Nach diesen Transaktionen besitzt er direkt 53.068 Aktien und gibt insgesamt 201.000 Aktien als wirtschaftlich gehalten an, einschlie脽lich Derivatepositionen. Die Verk盲ufe erfolgten unter einem am 20.02.2025 eingef眉hrten Rule-10b5-1-Plan und waren nicht-diskretion盲re Sell-to-Cover-Transaktionen zur Steuerzahlung. Die RSU-Zuteilung vestet 眉ber 18 Monate, wobei ab dem 15.02.2025 alle sechs Monate ein Drittel vestet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Allen Robert D. III
(Last) (First) (Middle)
C/O INVIVYD, INC.
1601 TRAPELO ROAD, SUITE 178
(Street)
WALTHAM MA 02451
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Invivyd, Inc. [ IVVD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 M 99,000 A (1) 99,000 D
Common Stock 08/18/2025 S 18,512(2) D $0.6502(3) 80,488 D
Common Stock 08/19/2025 S 27,420(2) D $0.5666(4) 53,068 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 08/15/2025 M 99,000 (5) (5) Common Stock 99,000 $0.00 201,000 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of Invivyd, Inc. (the "Company").
2. The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5801 to $0.7134, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.5524 to $0.6040, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
5. This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Remarks:
Exhibit 24.1: Power of Attorney
/s/ Jill Andersen attorney-in-fact for Robert D. Allen III 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did Invivyd (IVVD) insider Robert D. Allen III report on Form 4?

He reported vesting of 99,000 RSUs on 08/15/2025 and subsequent sell-to-cover sales of 18,512 shares on 08/18/2025 and 27,420 shares on 08/19/2025.

Why were shares sold by the reporting person in the Form 4 for IVVD?

The sales were sell-to-cover transactions executed pursuant to a non-discretionary Rule 10b5-1 plan to satisfy tax withholding obligations upon RSU vesting.

What prices were realized for the shares sold by the IVVD reporting person?

The filing reports weighted average prices of $0.6502 for the 08/18 sales and $0.5666 for the 08/19 sales; detailed per-trade prices fall within the disclosed ranges and are available on request.

How many shares does Robert D. Allen III beneficially own after these transactions?

After the reported transactions he directly beneficially owns 53,068 shares and reports total beneficial ownership of 201,000 shares when including derivative RSU holdings.

What is the RSU vesting schedule disclosed in the Form 4 for IVVD?

The RSU award vests over 18 months, with one-third vesting every six months following the grant date of 02/15/2025, subject to continuous service.
Stock IVVD logo
Invivyd

NASDAQ:IVVD

IVVD Rankings

#5006 Ranked by Market Cap
N/A Ranked by Dividends

IVVD Latest News

Aug 20, 2025
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
Aug 20, 2025
Invivyd Announces Proposed Public Offering of Common Stock
Aug 18, 2025
Invivyd Announces Continued Neutralizing Activity of PEMGARDA庐 (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (鈥淪tratus鈥�)
Aug 14, 2025
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Aug 14, 2025
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

IVVD Latest SEC Filings

Aug 20, 2025
[424B5] Invivyd, Inc. Prospectus Supplement (Debt Securities)
Aug 19, 2025
[Form 4] Invivyd, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Invivyd, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Invivyd, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Invivyd, Inc. Insider Trading Activity

IVVD Stock Data

69.71M
70.74M
41.12%
57.5%
2.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
WALTHAM